Skip to main content
Premium Trial:

Request an Annual Quote

OncoCyte Receives CLIA Certification for Cancer Dx Lab

NEW YORK (GenomeWeb) – OncoCyte said today that its Alameda, California clinical laboratory facility has received a CLIA certification of registration from the Centers for Medicare and Medicaid Services.

Certificates of registration allow labs to conduct moderate or high complexity testing ahead of being inspected for compliance with CLIA regulations, at which point they can receive a certificate of compliance.

In addition to its CLIA registration, OncoCyte said its lab has also now passed inspection by the California Department of Public Health, making it licensed and operational in that state. California is among a handful of states require licensing by their own regulatory bodies, as well as CLIA certification, in order for a lab to receive patient samples from those states.

The company plans to launch and offer its first assay, DetermaVu, from the lab in the fourth quarter of this year, pending results of two planned validation studies. DetermaVu is a noninvasive confirmatory lung cancer diagnostic, which measures a panel of mRNA markers in blood samples to predict which patients with positive lung imaging results have benign versus malignant nodules.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.